Pfizer to present exclusive new survey results on GP interactions with pharmacists

eyeforpharmaIan Hunter, Pharmacy Development Manager at Pfizer confirmed on Friday that he will be delivering a presentation at the 5th annual Patient Compliance & Communication conference. It will contain new data gathered from a study of 400 GP's and their interactions between pharmacists, the GPs familiarity with MURs and their impact on patient care.

In April 2005 the new contractual framework for community pharmacy ("the new contract") was introduced in the UK. In addition to traditional dispensing duties pharmacists were invited to participate in a new service, the medicines used review (MUR).

The MUR involves pharmacists undertaking structured concordance centered reviews with patients on multiple medicines, particularly those receiving medicines for long term conditions. The pharmacist consults with the patient to establish the patients actual use of medicines compared to the posology of their prescription. The review aims to help patients understand their therapy, identify any problems they are experiencing along with possible solutions. For this review to be most effective it is essential that pharmacists feedback information on the outcomes from the MUR to the patient’s GP so that both healthcare professionals have the same information available to them and act similarly if compliance is to be optimized.

In this study of 400 GPs we examined the interactions between GPs and pharmacists, GPs familiarity with MURs and their impact on patient care. The results will be explored at the Patient Compliance & Communication conference, June 11-12th 2008.

The early bird discount of €300 to this world-leading meeting expires March 5th, in just one weeks time. To register at this special price visit https://secure.firstconf.com/pharma/pceu2008/register.htm.

The full detailed brochure of all other presentations is available to download now at http://www.eyeforpharma.com/pceu2008/

About eyeforpharma
eyeforpharma is a leading global source of information for the pharmaceutical industry. Our reputation has been built on quality, in-depth conferences that have distinguished themselves from competitors by the depth and breadth of research we put into each conference to ensure it is covering the hottest and most pertinent issues of the industry. Months are spent talking directly to senior executives in the industry, as well as relevant consultants and journalists and well respected solutions providers.

eyeforpharma also provides a fortnightly newsletter to over 11 thousand leading executives from every major pharmaceutical company in the industry, and of course consultants, sponsors and academics as well.

The eyeforpharma wiki, launched last month, highlights our dedication to improving the communication between people in the industry and furthering learning and development within it.

For further information, please visit www.eyeforpharma.com.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech advance COVID-19 vaccine strat…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to...

New needle-free nasal vaccine shows promise for CO…

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mB...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Disparities in United States COVID-19 vaccine dist…

When reports showed COVID-19 vaccination rates were lower among racial/ethnic minority groups, most discussions focused on mistrust and misinformation among these populat...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

GSK signs agreement to support pandemic preparedne…

GSK plc (LSE/NYSE: GSK) announced it had signed a framework contract with the European Commission's (EC) Health Emergency Preparedness and Response Authority (HERA) for t...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...